Abstracts tagged "interleukins (IL) and osteoarthritis"

Abstract Number: 1974 • 2019 ACR/ARP Annual Meeting
The Rat Homolog to FX201, a Gene Therapy in Development for the Treatment of Osteoarthritis, Demonstrates Dose-Dependent Decreases in the Severity of Cartilage and Bone Lesions Following Anterior Cruciate Ligament Transection
Rebecca Senter ¹, Rogely Boyce², Monika Chabicovksy ³, Emily Walsh Martin ¹, Geneviève Langevin-Carpentier ⁴ and Neil Bodick ¹, ¹Flexion Therapeutics, Burlington, ²Beechy Ridge ToxPath LLC, Clay, ³MC Toxicology Consulting, Vienna, Austria, ⁴Charles River Laboratories, Senneville, Canada
Background/Purpose: Acute injury to the anterior cruciate ligament (ACL) is a common cause of posttraumatic OA in humans, and ACL transection (ACLT) in rats is…
Abstract Number: 445 • 2018 ACR/ARHP Annual Meeting
Interleukin-1β Inhibition with Canakinumab Associates with Reduced Rates of Total Hip and Knee Replacement (THR/TKR) and Osteoarthritis (OA) Symptoms: Exploratory Results from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Matthias Schieker¹, Linda Mindeholm¹, Jens Praestgaard², Celeste Scotti¹, Daniel Solomon³, Tom Thuren⁴, Kasper Dreyer⁵, Ronenn Roubenoff¹ and Paul M. Ridker⁶, ¹Novartis Institutes for Biomedical Research, Basel, Switzerland, ²Novartis Institutes for Biomedical Research, East Hanover, NJ, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Novartis Pharma AG, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Division of Preventive Medicine, Cardiovascular Diseases, Brigham and Women's Hospital, Boston, MA
Background/Purpose: In osteoarthritis (OA), there are no therapeutics to prevent disease progression. Canakinumab, a monoclonal antibody targeting interleukin-1β, reduced inflammation and cardiovascular events in the…
Abstract Number: 1187 • 2017 ACR/ARHP Annual Meeting
Chondroitin Sulfate/Glucosamine Hydrochloride Induce a Reduction in Adrenergic Serum Markers in Osteoarthritis Patients Similar to That Produced By Celecoxib
Marta Herrero¹, Pedro Zapater^2,3, Helena Martinez¹, Rubén Francés^3,4, Josep Vergés⁵ and Jose F Horga², ¹Clinical R&D Area, Bioiberica, SAU, Barcelona, Spain, ²Pharmacology Department, Miguel Hernández University, Alicante, Spain, ³CIBERehd. Carlos III Institute, Madrid, Spain, ⁴Medicine Department, Miguel Hernández University, Alicantes, Spain, ⁵Osteoarthritis Foundation International, Barcelona, Spain
Background/Purpose: Inflammation in osteoarthritis (OA) has been characterized by infiltration of immune cells and secretion of cytokines into synovial tissues. Noradrenaline levels, sympathetic nerve fiber…
Abstract Number: 1006 • 2014 ACR/ARHP Annual Meeting
Interleukin-4 As Promising, Anti-Inflammatory Transgene for Gene Therapeutic Application in Joint Diseases
Annemarie Lang¹, Johannes Neuhaus², Moritz Pfeiffenberger³, Erik Schroeder⁴, Frank Buttgereit⁵, Michael F. G. Schmidt³ and Timo Gaber⁶, ¹Berlin-Brandenburg School of Regenerative Therapies (BSRT), Berlin, Germany, ²Department of Veterinary Medicine, Research Center of Medical Technology and Biotechnology, Bad Langensalza, Germany, ³Department of Veterinary Medicine, Institute of Immunology, Freie Universität Berlin, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ⁵Charité University Hospital, Berlin, Germany, ⁶Berlin-Brandenburg Center of Regenerative Therapies (BCRT), Berlin, Germany
Background/Purpose Interleukin- 4 (IL-4), a Th2-cell released immunomodulatory factor, has potent chondroprotective and anti-inflammatory properties able to inhibit the synthesis of IL-1β and TNFα, and…
Abstract Number: 19 • 2012 ACR/ARHP Annual Meeting
Stress-Induced Cartilage Degradation Does Not Depend On NLRP3-Inflammasome in Osteoarthritis
Carole Bougault¹, Marjolaine Gosset², Xavier Houard³, Colette Salvat⁴, Lars Godmann⁵, Thomas Pap⁵, Claire Jacques¹ and Francis Berenbaum⁶, ¹Ur-4, Pierre et Marie Curie University Paris VI, Paris, France, ²EA 2496, Paris Descartes University, Montrouge, France, ³Sorbonne Universités, UPMC Univ Paris 06, UMRS 938 and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France, ⁴UR4, University Pierre and Marie Curie, Paris, France, ⁵Institute of Experimental Muskuloskeletal Medicine, University Hospital Münster, Münster, Germany, ⁶Rheumatology, AP-HP, St Antoine Hospital, Paris, France
Background/Purpose: The cartilage matrix breakdown in osteoarthritis (OA) is due to both abnormal mechanical stress and activation of catabolic processes involving metalloproteinases (MMPs). Currently, IL-1beta…
Abstract Number: 2 • 2012 ACR/ARHP Annual Meeting
Microrna-558 Regulates the Expression of Cyclooxygenase-2 and IL-1beta Responses in Human Articular Chondrocytes
Su Jin Park¹, Eun-Jeong Cheon² and Hyun Ah Kim², ¹Department of Internal Medicine, Hallym University Sacred Heart Hospital, Kyunggi, South Korea, ²Department of internal medicine, Hallym University Sacred Heart Hospital, Kyunggi, South Korea
Background/Purpose: Osteoarthritis (OA) is a chronic degenerative joint disease in which multiple factors contribute to cartilage degradation. It is widely accepted that excess production of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].